Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.58
IPCI's Cash to Debt is ranked higher than
64% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. IPCI: 3.58 )
IPCI' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 3.58

Equity to Asset 0.62
IPCI's Equity to Asset is ranked higher than
70% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IPCI: 0.62 )
IPCI' s 10-Year Equity to Asset Range
Min: -1.36   Max: 1
Current: 0.62

-1.36
1
F-Score: 5
Z-Score: 3.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -38.55
IPCI's Operating margin (%) is ranked higher than
76% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. IPCI: -38.55 )
IPCI' s 10-Year Operating margin (%) Range
Min: -1046100   Max: -414.8
Current: -38.55

-1046100
-414.8
Net-margin (%) -99.11
IPCI's Net-margin (%) is ranked higher than
71% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. IPCI: -99.11 )
IPCI' s 10-Year Net-margin (%) Range
Min: -914800   Max: -394.86
Current: -99.11

-914800
-394.86
ROE (%) -344.45
IPCI's ROE (%) is ranked higher than
50% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. IPCI: -344.45 )
IPCI' s 10-Year ROE (%) Range
Min: -235.42   Max: -34.13
Current: -344.45

-235.42
-34.13
ROA (%) -112.38
IPCI's ROA (%) is ranked higher than
53% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. IPCI: -112.38 )
IPCI' s 10-Year ROA (%) Range
Min: -343.98   Max: -32.43
Current: -112.38

-343.98
-32.43
ROC (Joel Greenblatt) (%) -206.88
IPCI's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. IPCI: -206.88 )
IPCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9384   Max: -512.6
Current: -206.88

-9384
-512.6
Revenue Growth (%) -14.90
IPCI's Revenue Growth (%) is ranked higher than
69% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. IPCI: -14.90 )
IPCI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -13.9
Current: -14.9

EBITDA Growth (%) 2.40
IPCI's EBITDA Growth (%) is ranked higher than
80% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. IPCI: 2.40 )
IPCI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 46.2
Current: 2.4

0
46.2
EPS Growth (%) 4.90
IPCI's EPS Growth (%) is ranked higher than
82% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. IPCI: 4.90 )
IPCI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.3
Current: 4.9

0
65.3
» IPCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.60
IPCI's P/B is ranked higher than
63% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. IPCI: 12.60 )
IPCI' s 10-Year P/B Range
Min: 6.88   Max: 496
Current: 12.6

6.88
496
P/S 7.80
IPCI's P/S is ranked higher than
85% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. IPCI: 7.80 )
IPCI' s 10-Year P/S Range
Min: 6.5   Max: 317
Current: 7.8

6.5
317
EV-to-EBIT -19.54
IPCI's EV-to-EBIT is ranked higher than
57% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IPCI: -19.54 )
IPCI' s 10-Year EV-to-EBIT Range
Min: -55.9   Max: -2.9
Current: -19.54

-55.9
-2.9
Current Ratio 2.11
IPCI's Current Ratio is ranked higher than
60% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. IPCI: 2.11 )
IPCI' s 10-Year Current Ratio Range
Min: 0.37   Max: 94.99
Current: 2.11

0.37
94.99
Quick Ratio 2.11
IPCI's Quick Ratio is ranked higher than
63% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. IPCI: 2.11 )
IPCI' s 10-Year Quick Ratio Range
Min: 0.37   Max: 94.99
Current: 2.11

0.37
94.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 32.20
IPCI's Price/Net Cash is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. IPCI: 32.20 )
IPCI' s 10-Year Price/Net Cash Range
Min: 0.02   Max: 89
Current: 32.2

0.02
89
Price/Net Current Asset Value 24.20
IPCI's Price/Net Current Asset Value is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. IPCI: 24.20 )
IPCI' s 10-Year Price/Net Current Asset Value Range
Min: 0.02   Max: 89
Current: 24.2

0.02
89
Price/Tangible Book 12.10
IPCI's Price/Tangible Book is ranked higher than
69% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. IPCI: 12.10 )
IPCI' s 10-Year Price/Tangible Book Range
Min: 0.02   Max: 258
Current: 12.1

0.02
258
Price/Median PS Value 0.10
IPCI's Price/Median PS Value is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. IPCI: 0.10 )
IPCI' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 84.62
Current: 0.1

0.13
84.62
Earnings Yield (Greenblatt) -5.10
IPCI's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. IPCI: -5.10 )
IPCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.1   Max: 0
Current: -5.1

-5.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I.Canada, I4A.Germany
IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, they have developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva Nov 22 2014
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva Nov 20 2014
Intellipharmaceutics Announces Appointment of New Chief Financial Officer Nov 18 2014
Intellipharmaceutics Announces Appointment of New Chief Financial Officer Nov 18 2014
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an... Oct 27 2014
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an... Oct 27 2014
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of... Oct 22 2014
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of... Oct 22 2014
Intellipharmaceutics Announces Third Quarter 2014 Results Oct 15 2014
Profound Medical Appoints Shameze Rampertab as Chief Financial Officer Oct 15 2014
[$$] Two Drug Firms Fighting Opioid Abuse Oct 09 2014
Intellipharmaceutics Announces Resignation of Chief Financial Officer Sep 30 2014
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher? Sep 16 2014
IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% Sep 08 2014
Intellipharmaceutics Intl upgraded by Maxim Group Sep 05 2014
Intellipharmaceutics' Oxycodone Program to Prevent Overdose Aug 29 2014
Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose... Aug 28 2014
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert Jul 29 2014
5 Stocks Ready for Breakouts Jul 28 2014
Why Intellipharmaceutics (IPCI) Stock Is Down Today Jul 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK